Clinical Trials Logo

Clinical Trial Summary

In spite of aggressive approaches to prevent and treat osteoporosis, it remains one of the most costly and debilitating diseases associated with aging. The pursuit of alternative approaches for preventing bone loss has included the investigation of a number of promising plant-based foods that can be incorporated into the diet. This project is an extension of our pre-clinical studies with tart cherry, designed to determine whether the findings from our animal study can be extended to humans. Thus, the purpose of this project is to investigate the dose-dependent effect of tart cherry juice consumption on biomarkers of bone metabolism in women, aged 65-80 years. The hypothesis to be tested is that three months of tart cherry supplementation will improve bone biomarkers in a dose-dependent manner. Moreover, these improvements in bone metabolism will correspond to a decrease in markers of inflammation and oxidative stress.


Clinical Trial Description

Tart cherries are an excellent course of phenolic compounds and anthocyanins, and in pre-clinical studies have been shown to prevent age-related bone loss. Based on these findings, this pilot study was designed to investigate the effects of three months of tart cherry juice supplementation on improving markers of oxidative stress and bone metabolism in older women. Women (n=30), aged 65-80 yrs, will be recruited for the study and randomly assigned to one of two doses of tart cherry juice (8 or 16 fl oz) per day prepared from a Montmorency cherry concentrate (King Orchards, Central Lake, MI). Study participants will complete two study visits to the Nutritional Sciences Clinical Research Center. At the first visit, informed consent will be obtained and relevant medical history and anthropometric measures will be taken by the research team. A blood draw will be performed to assess baseline, biochemical markers of bone metabolism and inflammation as well as indicators of oxidative status. A physical activity and food frequency questionnaire will be completed by each study participant. Whole body, hip and spine bone density (DXA) scan will be performed by certified bone densitometrist. A 3-month final visit will be scheduled for all study participants in which most of the procedures described at baseline (except DXA) will be repeated. Change in primary and secondary outcome measures (i.e., bone, inflammation and oxidative stress biomarkers) will be assessed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04167150
Study type Interventional
Source Oklahoma State University
Contact
Status Completed
Phase N/A
Start date June 6, 2017
Completion date May 31, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03931109 - Circulating miRNA in Primary Hyperparathyroidism
Not yet recruiting NCT03232476 - Effect of Mechanical Loading With PTH on Cortical Bone Phase 4
Completed NCT02884401 - Peri-implant Bone Changes in Post-menopausal Osteoporotic Women N/A
Completed NCT00073190 - Patient- and Physician-Based Osteoporosis Education Phase 1
Completed NCT00402441 - Risedronate in the Prevention of Osteoporosis in Postmenopausal Women Phase 4
Completed NCT03710889 - Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption Phase 3
Completed NCT00010712 - Effects of Black Cohosh on Menopausal Hot Flashes Phase 2
Recruiting NCT05058976 - Romosozumab Use to Build Skeletal Integrity Phase 4
Recruiting NCT05405894 - Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Recruiting NCT03337971 - Nutritional Supplement and Bone Health in Post-Menopausal Women N/A
Completed NCT03701113 - Milk Protein and Bone Health in Postmenopausal Women N/A
Completed NCT01381588 - The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women N/A
Completed NCT00383422 - Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis Phase 3
Completed NCT00549965 - Satisfaction and Compliance of Risedronate in PMO Phase 4
Completed NCT00035256 - Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis Phase 4
Completed NCT01386281 - Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
Completed NCT05266261 - Use of Ibandronate in Diabetic Patients N/A
Recruiting NCT04964388 - Effect of GLP-1 Receptor Agonists on Trabecular Bone Score Phase 2
Active, not recruiting NCT03623633 - Comparative Antiresorptive Efficacy Discontinuation of Denosumab Phase 4
Recruiting NCT05575167 - Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)